Hanley GE, Kaur P, Berchuck A, et al. - Given studies assessing survival in individuals with ovarian cancer after use of statins or β-blockers has been conflicting, researchers herein assessed the link between statin or β-blocker use among all persons diagnosed with an epithelial ovarian cancer in British Columbia, Canada between 1997 and 2015. For this purpose, they used time-dependent analyses. For 4,207 persons with ovarian cancer, population-based administrative data were linked. To estimate the link between statin or β-blocker use and survival, they employed Cox proportional hazards models. Findings demonstrated improved survival in ovarian cancer patients in relation to postdiagnosis statin use. In view of the consistency of this revelation in the literature, a randomized clinical trial of statin use in people with ovarian cancer is advised. No statistically significant link was found between β-blocker use and survival.